Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenqigui oral liquid for bone marrow suppression in small cell lung cancer chemotherapy
ChiCTR2100044923Phase 4Recruiting
- Sponsor
- Chengdu University of Traditional Chinese Medicine
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of shenqigui in small cell lung cancer (SCLC) (2 arms), sponsored by Chengdu University of Traditional Chinese Medicine. Primary endpoint: Bone marrow suppression degree grading and incidence. Started Apr 2021; status: recruiting.
02
Drugs
shenqigui
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100044923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044923.